Biodegradable sustained-release medicament stent for TMR and preparation method

Abstract

The invention discloses a transmural myocardial revascularization biodegradable drug controlled-release bracket and a preparation method thereof. The transmural myocardial revascularization biodegradable drug controlled-release bracket comprises a hollow tube with the inner diameter of 0.2mm to 1mm, the wall thickness of 0.1 to 0.5mm and the length of 0.1 to 0.5mm, the wall of the tube is provided with a hole that runs through the wall, and the material of the tube is biodegradable polymer that is loaded with cell growth factors and / or heparin. The bracket of the invention can prevent the hole channel of transmural myocardial revascularization (TMR) from closing and keep the blood flow perfusion unobstructed; the bracket can be degraded into micro molecules to be excreted to the outside of the body shortly after the supporting function and drug-controlling function are completed, thus avoiding adverse impact caused by staying in the body for a long time; the drug controlled-release growth factors can promote the revascularization and the heparin has the function of anticoagulation, thus being beneficial to the restoration of partial ischemic myocardium.

Description

technical field [0001] The invention relates to a biodegradable stent and a preparation method thereof, in particular to a biodegradable drug slow-release stent for revascularization of transmural myocardial blood vessels and a preparation method thereof. Background technique [0002] Transmural myocardial revascularization (TMR) is a new surgical technique for refractory angina pectoris through transmural myocardial perforation using laser or mechanical methods. It is primarily indicated for the treatment of patients with advanced angina pectoris who are undergoing coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) indications. Its role in reducing angina pectoris, improving ischemic myocardial perfusion, and improving heart function has been widely concerned. Recent studies have shown that after TMR, the transmural myocardial vascular channels are occluded due to blood coagulation, which cannot be kept open for a long time, and...

AI Technical Summary

Problems solved by technology

However, the half-life of growth factors in the blood circulation is very short, only tens of minutes, and the targeting is poor, so it is difficult to exert a long-term and continuous pro-angiogenic effect. Systemic large-scale application will cause blood pressure drop and potential tumor-promoting Adverse side effects such as mutagenesis, the therapeutic effect can be improved through the slow and controlled release technology of drugs

[0005] Due to the lack of research on myocardial stents, stents for other purposes cannot fully meet the needs of myocardial revascularization, and the released drugs are also quite different. Therefore, there is an urgent need for a drug-sustained-release stent that can not only prevent the myocardium from closing itself, It can also promote the formation of vascular endothelium on the wall of the hole, which will be the optimization of transmural myocardial revascularization, play a certain role in the treatment of myocardial ischemic diseases, and provide the necessary support for the real whole myocardial revascularization. basic condition

Images